EATRIS: Europe Built a Bridge from Discovery to Medical Development

A European capability between discovery and development

Europe built EATRIS to connect a promising biomedical finding with the expertise needed to develop it responsibly. The European Infrastructure for Translational Medicine combines specialised academic facilities, clinical knowledge and development support across borders. Its achievement is practical: a research team can seek capabilities beyond its own institution instead of trying to recreate an entire development chain locally. For researchers and small companies, the useful starting question is which missing piece of evidence would change the next decision.

Translation means developing a discovery towards a usable intervention, diagnostic or research tool. A signal found in one laboratory may still need an independently tested assay, appropriate samples, a manufacturing method or a credible clinical development plan. EATRIS concentrates on preclinical and early clinical development. Its five scientific platforms cover advanced therapy medicinal products, small molecules, vaccines, biomarkers, and imaging and tracing. These are connected capabilities rather than five guaranteed routes to an approved product.

EATRIS is a non-profit European Research Infrastructure Consortium, an ERIC. The Commission’s active ERIC register distinguishes this legal infrastructure from an EU executive agency. Academic institutions deliver specialised work through a distributed organisation; European legal arrangements make that cooperation durable. The 2025 annual-report overview records Slovakia becoming its fifteenth member. That dated milestone is more informative than treating an older fourteen-country description as a current roll-call, or assuming every EU country participates.

Ask which evidence is missing

The scientific contribution can be quite specific. EATRIS’s biomarker platform describes independent validation in different clinical groups, standardised assay development, access to clinical samples and expert appraisal of clinical relevance. A biomarker associated with disease in an initial dataset is not automatically useful for choosing treatment. Testing whether the measurement is dependable and whether the finding holds in another group helps distinguish a publishable observation from evidence on which a later development decision can reasonably rest.

The infrastructure also helps people ask the right development question before commissioning another experiment. Its Translational Feasibility Assessment supports non-profit funders and their investigators with multidisciplinary scrutiny of medical need, regulatory route, intellectual property, development tools and market context. A technically impressive result may address the wrong clinical problem or need a different validation sequence. Shared expertise can expose that early, when changing direction is less costly than repeating a poorly designed programme.

A practical route for a research team

Consider an illustrative team in Riga developing a blood-based biomarker. Its discovery study is encouraging, but the next funding application needs a plan for independent validation. Rather than requesting ‘European collaboration’ in general, the team could ask for expertise in assay reproducibility, an appropriately characterised second cohort and clinical interpretation. These are hypothetical needs, not a reported EATRIS project or a claim that a particular sample collection is available. The capability request is specific enough to assess.

The team’s first brief should state the intended use, existing evidence, missing test, sample requirements, available budget and decision that the result will support. The funding-support page offers free matching to potential European academic consortium partners; applicants then contact prospective partners themselves. Matching is an introduction, not an agreement to supply samples or perform research. Confirm the work scope, price or funding route, responsibilities, access conditions, confidentiality and intellectual-property terms before committing a partner to a proposal.

Regulatory expertise belongs early in that conversation. EATRIS offers development and regulatory support, including assistance with scientific-advice applications and preclinical or clinical plans. Advising an applicant does not make EATRIS the authorising body. The specific RIS notice currently says its Regulatory Information System is being redeveloped and is unavailable to external visitors. Researchers should use the current service contact rather than build a project timetable around an older general description of an accessible database.

Bring patients and complementary expertise into the plan

Patients can help define whether the intended use matters. EATRIS, the European Patients’ Forum and the European AIDS Treatment Group launched the Patient Engagement Resource Centre in March 2023, with guidance, training and practical material for early biomedical research. In the illustrative biomarker project, engagement might reveal that a supposedly convenient sampling schedule is burdensome, or that the proposed outcome does not capture a meaningful improvement. This is an editorial example of applying engagement, not evidence of a finished clinical benefit.

European research cooperation works best when neighbouring responsibilities remain visible. The EU-AMRI alliance brings EATRIS together with BBMRI-ERIC and ECRIN-ERIC as complementary infrastructures. A project may need biobanking expertise, translational development and multinational clinical research support at different points. Those services can connect without becoming one undifferentiated institution. The matrix below is a planning aid: it helps identify the role to consult rather than implying that an infrastructure can take over every sponsor, ethics or data-protection responsibility.

What is operational, and what is still being developed?

There is also continuing investment in the infrastructure itself. The CORDIS record for EATRIS-CONNECT gives a project period from 1 May 2024 to 30 April 2027. It records €4,999,668.75 in total costs and €3,999,735 in EU contribution. Those are different quantities. The project aims to strengthen digital readiness, tools and national nodes; as of 13 November 2026, its scheduled end is still ahead. A funded objective should be assessed against delivered services rather than announced as completed transformation.

This is a different achievement from the shared discovery and data capacity of EMBL, the European medicines assessment network, or cross-border rare-disease clinical expertise. EATRIS connects the development work between an experimental finding and a credible medical application. Participation is research support, not patient self-referral, marketing authorisation or proof that an experimental intervention works.

Shared capability, usable from a local laboratory

Europeans can be proud of this organised capability: expertise can stay in national laboratories while becoming easier to combine across borders. The next test is whether teams can obtain suitable services, produce reproducible evidence and make better decisions, including a justified decision to stop. Our Proud Europe hub follows the institutions and infrastructure that make such shared capacity possible. Here, European scale gives a small research team a larger set of practical options.